Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University of Arizona
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04838301CT.gov Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | — | Recruiting | — | — | — |
NCT03748303CT.gov Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study | — | Terminated | — | — | — |
NCT02221622CT.gov Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allopregnan-3.Alpha.-Ol-20-One (this asset) | University of Arizona | P2 | B · 60 |
| 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE | Akiva Mintz | P4 | BBB |
| Memantine | Carnot Laboratories | P4 | BBB |
| Escitalopram | NYU Langone Health | P4 | BBB |
| Flortaucipir | Eli Radiopharma | P4 | BBB |
| Rivastigmine | Anhui Provincial Hospital | P4 | BBB |
| Florbetaben | National Institute of Mental Health (NIMH) | P4 | BBB |
| 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) | Anhui Provincial Hospital | P4 | BBB |
| Sertraline | AstraZeneca | P4 | BBB |
+42 more in the Alzheimer Disease cohort
Other indications for Allopregnan-3.Alpha.-Ol-20-One
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Postpartum Depression | — | P3 | BBB · 72 |
| Post-Traumatic Epilepsy | — | P2 | B · 57 |
| Traumatic Brain Injury | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allopregnan-3.Alpha.-Ol-20-One in Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allopregnan-3alpha-ol-20-one-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →